Cargando…
Integrated genetic and epigenetic analysis of myxofibrosarcoma
Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050269/ https://www.ncbi.nlm.nih.gov/pubmed/30018380 http://dx.doi.org/10.1038/s41467-018-03891-9 |
_version_ | 1783340297680322560 |
---|---|
author | Ogura, Koichi Hosoda, Fumie Arai, Yasuhito Nakamura, Hiromi Hama, Natsuko Totoki, Yasushi Yoshida, Akihiko Nagai, Momoko Kato, Mamoru Arakawa, Erika Mukai, Wakako Rokutan, Hirofumi Kawai, Akira Tanaka, Sakae Shibata, Tatsuhiro |
author_facet | Ogura, Koichi Hosoda, Fumie Arai, Yasuhito Nakamura, Hiromi Hama, Natsuko Totoki, Yasushi Yoshida, Akihiko Nagai, Momoko Kato, Mamoru Arakawa, Erika Mukai, Wakako Rokutan, Hirofumi Kawai, Akira Tanaka, Sakae Shibata, Tatsuhiro |
author_sort | Ogura, Koichi |
collection | PubMed |
description | Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS. |
format | Online Article Text |
id | pubmed-6050269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60502692018-07-23 Integrated genetic and epigenetic analysis of myxofibrosarcoma Ogura, Koichi Hosoda, Fumie Arai, Yasuhito Nakamura, Hiromi Hama, Natsuko Totoki, Yasushi Yoshida, Akihiko Nagai, Momoko Kato, Mamoru Arakawa, Erika Mukai, Wakako Rokutan, Hirofumi Kawai, Akira Tanaka, Sakae Shibata, Tatsuhiro Nat Commun Article Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of MFS based on the results of whole-exome sequencing (N = 41), RNA sequencing (N = 29), and methylation analysis (N = 41), using 41 MFSs as a discovery set, and subsequent targeted sequencing of 140 genes in the entire cohort of 99 MFSs and 17 MFSs' data from TCGA. Fourteen driver genes are identified, including potentially actionable therapeutic targets seen in 37% of cases. There are frequent alterations in p53 signaling (51%) and cell cycle checkpoint genes (43%). Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1, and novel oncogenic BRAF fusion gene are identified. Methylation patterns cluster into three subtypes associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS. Nature Publishing Group UK 2018-07-17 /pmc/articles/PMC6050269/ /pubmed/30018380 http://dx.doi.org/10.1038/s41467-018-03891-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Ogura, Koichi Hosoda, Fumie Arai, Yasuhito Nakamura, Hiromi Hama, Natsuko Totoki, Yasushi Yoshida, Akihiko Nagai, Momoko Kato, Mamoru Arakawa, Erika Mukai, Wakako Rokutan, Hirofumi Kawai, Akira Tanaka, Sakae Shibata, Tatsuhiro Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title | Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title_full | Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title_fullStr | Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title_full_unstemmed | Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title_short | Integrated genetic and epigenetic analysis of myxofibrosarcoma |
title_sort | integrated genetic and epigenetic analysis of myxofibrosarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050269/ https://www.ncbi.nlm.nih.gov/pubmed/30018380 http://dx.doi.org/10.1038/s41467-018-03891-9 |
work_keys_str_mv | AT ogurakoichi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT hosodafumie integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT araiyasuhito integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT nakamurahiromi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT hamanatsuko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT totokiyasushi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT yoshidaakihiko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT nagaimomoko integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT katomamoru integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT arakawaerika integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT mukaiwakako integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT rokutanhirofumi integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT kawaiakira integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT tanakasakae integratedgeneticandepigeneticanalysisofmyxofibrosarcoma AT shibatatatsuhiro integratedgeneticandepigeneticanalysisofmyxofibrosarcoma |